Last reviewed · How we verify
FSH+LH
FSH and LH are gonadotropins that stimulate follicle development and ovulation in women, used to induce ovarian stimulation for assisted reproductive technologies.
FSH and LH are gonadotropins that stimulate follicle development and ovulation in women, used to induce ovarian stimulation for assisted reproductive technologies. Used for Infertility treatment via controlled ovarian hyperstimulation for assisted reproductive technology (ART), In vitro fertilization (IVF) and embryo transfer.
At a glance
| Generic name | FSH+LH |
|---|---|
| Sponsor | Instituto Valenciano de Infertilidad, IVI VALENCIA |
| Drug class | Gonadotropin combination |
| Target | FSH receptor (FSHR) and LH receptor (LHCGR) |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Infertility |
| Phase | Phase 3 |
Mechanism of action
Follicle-stimulating hormone (FSH) promotes the growth and maturation of ovarian follicles, while luteinizing hormone (LH) triggers the final maturation and ovulation of the egg. This combination therapy mimics the natural hormonal cycle to produce multiple mature eggs for fertility treatment. The combination is used in controlled ovarian hyperstimulation protocols for in vitro fertilization (IVF) and other assisted reproductive procedures.
Approved indications
- Infertility treatment via controlled ovarian hyperstimulation for assisted reproductive technology (ART)
- In vitro fertilization (IVF) and embryo transfer
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Headache
- Injection site reactions
- Abdominal pain/bloating
- Nausea
Key clinical trials
- Follow-up of Sequential Chemotherapy and Stimulation for Fertility Preservation in Young Patients With Breast Cancer (NA)
- A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) (PHASE3)
- Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring (PHASE1, PHASE2)
- Exogenous Progesterone as Ovulation Trigger (PHASE4)
- Metformin Versus Myo-inositol in the Management of Polycystic Ovarian Disease: A Comparative Study (PHASE1)
- TMS-Induced LH Response in Healthy Women in Luteal Phase (NA)
- Comparison of Sequential CFA vs CFA +rFSH for Elective Fertility Preservation. (PHASE3)
- IVF Outcomes With Time-Lapse Culture: Comparison Between PPOS and GnRH Antagonist Protocols (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FSH+LH CI brief — competitive landscape report
- FSH+LH updates RSS · CI watch RSS
- Instituto Valenciano de Infertilidad, IVI VALENCIA portfolio CI